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Background
Lymphodepletion with subsequent reconstitution and
active-specific tumour cell vaccination (LRAST) during
the homeostatic proliferation is a promising approach in
cancer immunotherapy. While tumour specific response
is evident under LRAST regime, simultaneous induction
of potentially immunosuppressive immature myeloid
cells (MDSC) may limit the therapeutic efficacy. Follow-
ing LRAST MDSC can potentially be derived from the
host or the donor cell pool. Aim of the study was to
analyse the role of granulocytic (G-MDSC: CD11b+
Ly6G+ Ly6C+ ) and monocytic (Mo-MDSC: CD11b+
Ly6G- Ly6C+) MDSC and to track their fate in the reci-
pient mouse following LRAST.
Material and methods
Female C57BL/6 (Ly5.2) mice were challenged with
tumour by subcutaneous injection of 5×104 vital D5
melanoma cells and lymphodepleted 3 days later by i.p.
application of 200mg/kg cyclophosphamide. After 24 h
mice were reconstituted with i.v. injection of 2×107 sple-
nocytes from naïve B6.SJL-PtprcaPepcb/BoyCrl (Ly5.1)
mice followed by vaccination with 1×107 irradiated
mGM-CSF-producing D5G6 cells. Mice lacking tumour
challenge, lymphodepletion, or tumour vaccination were
included as controls. Splenocytes, peripheral blood cells
and lymph node cells were analyzed by 8 color flow cyto-
metry at days 3, 10 and 23. Induction of tumour-specific
T cells in tumour vaccine draining lymph nodes was eval-
uated in vitro by tumour specific IFN-g secretion assays.
Results
A pronounced increase in host G- and Mo-MDSC was
observed in spleens of both lymphodepleted and vacci-
nated groups between day 3 and 10. A decrease of
T-cell subsets, including memory T-cells, and natural
killer (NK) cells was detected at day 10. Consecutively
to the rapid decline of MDSC after day 10 a numeric
gain in the T-cell fraction was observed. In contrast NK
cells remained at a low level until day 23. Donor G- and
Mo-MDSC were detected at low frequencies at all time
points. Donor MDSC as identified by Ly5.1 slightly
increased between day 3 and 10 followed by a decline
after day 10. The reconstituted cell fraction predomi-
nantly consisted of T-cells (up to 29.7% of leukocytes).
Helper and effector T-cells were continuously increasing
during the observed period of time while memory type
T-cells (CD8+ Gr1+) were being suppressed.
Conclusions
The elevated numbers of MDSC at day 10 after treatment
may inhibit the induction of tumor specific T cells. There-
fore depleting MDSC in the recipient mouse with anti-
Gr1 antibody in the early phase of the LRAST treatment
could be a promising approach to improve anti-tumour
efficacy.
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